^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia

Published date:
04/29/2021
Excerpt:
High CIP2A levels correlated with inferior progression-free survival (p = 0.04) and with worse freedom from progression (p = 0.03), and these effects were confined to dasatinib recipients.
DOI:
10.3390/cancers13092155